Current pharmaceutical drugs for depression seem to be causing more harm than good to their users, with some patients developing a resistance to treatments while others become dependent on the treatments. This may be a reason for the increase in interest in the use of psychedelic drugs as alternative and potentially safer treatments for depression and other mental health conditions.
The first time psychedelics were studied as a potential mental-health treatment was several decades ago, when researchers studied the therapeutic potential of LSD. However, as decades passed and various national and international drug policies were implemented, further research exploring the therapeutic potential of these mind-altering substances was restricted as was the researchers’ access to those substances.
Things may be looking up however, as the easing of some of these laws continues. More states across the United States are implementing laws that favor the study and use of psychedelics as well as the medicinal and recreational use of marijuana. In the November elections, Oregonian voters approved access to psychedelic drugs for therapeutic use. This change makes it easier for researchers to conduct studies on these drugs while also making it easier for individuals to access the drugs.
As previously mentioned, the drugs being prescribed to help manage depression currently are not effective for a large number of those who use them, which indicates the need to widen treatment options. Just as with conventional antidepressant therapy, there’s a chance that the most effective means of administering these psychoactive medications as treatment for depressions would be alongside some form of counseling or therapy.
This may present new challenges to therapists and counselors, as these mind-altering substances have been known to elicit different reactions in different people. It would be important for a therapist or counselor to know how to effectively assess a situation and how to respond to these different reactions. This highlights the need for specialist training.
However, before these alternative forms of treatment can be declared safe, efficient, and approved and then brought to the market, the perception of these substances need to examined. The psychedelic medications used for therapy contain only micro-doses of the substance, making them safer than illicit sources. However, people’s fears may distort their views on these medications, which may actually be safer than conventional medicine. This perception may be a significant barrier to the introduction and acceptance of psychedelic medicines in the treatment of mental-health conditions such as depression.
There is a lot to be discovered and learned about the efficacy of psychedelics as treatment options. Key to this, however, is the ability for potential users and others to not allow their prejudices and fears to prevent themselves or loves ones who may be suffering from a mental condition access to potentially life-changing treatment. Opening minds to the possibilities is essential to change.
Many companies are opting for a science-driven approach to psychedelic product development. For instance, Cybin Inc. (NEO: CYBN) is working closely with the Centre for Psychedelic Science in Toronto, Canada, as it focuses on the pharmaceutical development of psychedelic products.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
